Medically Reviewed by: Dr. Dipak Ladda, M.D.
Expertise: Consultant Pathologist
Last Updated: July 18, 2026
Medical Analysis
Terminal Deoxynucleotidyl Transferase (TdT): Enzyme Structure, Biological Function, and Clinical Diagnostic Utility
Introduction to TdT: The Template-Independent DNA Polymerase
Terminal deoxynucleotidyl transferase (TdT), also known as DNA nucleotidylexotransferase (DNTT) or terminal transferase, is a specialized, unique DNA polymerase enzyme [1, 2]. Unlike standard polymerases that require a template to synthesize DNA, TdT is defined as a template-independent DNA polymerase [1, 9]. Its primary biochemical function is to catalyze the addition of nucleotides to the 3′-OH end of DNA strands. In human physiology, this enzyme is specifically expressed in immature, pre-B, and pre-T lymphoid cells [10, 14]. It is normally found in cortical thymocytes, immature hematopoietic stem cells, and is a hallmark feature in the cells of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma [7, 8, 10, 11].
Structure and Biochemical Properties of TdT
TdT is a nuclear enzyme with a molecular size of approximately 58 kDa [1, 13]. A defining characteristic of its biochemical activity is that it requires either magnesium (Mg2+) or cobalt (Co2+) ions as essential cofactors for its enzymatic function [1, 9]. The structural complexity of TdT is often illustrated through its distinct functional domains, including the “fingers,” “thumb,” and “palm” regions, which coordinate the binding of the DNA primer and the incoming nucleotides [2, 13]. The interaction between TdT, the DNA primer, and the cation cofactors is critical for the catalytic cycle where nucleotides are added sequentially to the 3′ end of the DNA initiator (ssDNAn) to form an elongated strand (ssDNAn+1), releasing pyrophosphate (PPi) as a byproduct [9].
The Role and Biological Functions of TdT
TdT plays a vital role in the development and variation of the immune system. Its functions are diverse and clinically significant:
V(D)J Recombination: TdT is critical during lymphocyte development, where it adds random nucleotides to the junctions of gene segments [3, 15]. This process significantly increases the diversity of antigen receptors, allowing the immune system to recognize a vast array of pathogens [4, 5].
Molecular Biology Applications:
Labeling: TdT is used to add labeled nucleotides (either radioactive or non-radioactive) to the 3′ ends of DNA fragments [1, 2].
Tail Creation: It can add homopolymeric tails (e.g., poly(dA)) to the 3′ ends of DNA, a technique useful for creating “sticky ends” on blunt-ended DNA molecules [9].
TUNEL Assay: The Terminal deoxynucleotidyl transferase dUTP Nick End Labeling (TUNEL) assay utilizes TdT to detect apoptotic (dying) cells by labeling the fragmented DNA [1, 12].
cDNA Synthesis: It is employed in cDNA synthesis, specifically for second-strand synthesis and the Okayama-Berg method [2, 13].
Other Uses: It finds utility in DNA sequencing (such as the Maxam-Gilbert method), de novo oligonucleotide synthesis, and immunohistochemistry/flow cytometry to detect immature T and B cells [12, 14].
Clinical Indications for TdT Testing
TdT testing is a critical diagnostic component for various haematological malignancies. It is particularly indicated in the evaluation of:
Lymphoblastic lymphoma [7, 14].
Lymphoblastic leukemia [6, 7, 11].
Acute myeloid leukemia [12, 14].
Chronic Myeloid Leukemia (CML) [8, 14].
Methods of Detection and Sample Collection
TdT is used to label 3′ hydroxyl DNA ends, which can then be detected via:
Fluorescence Method: Using Fluorescein-dUTP [12].
Immunohistochemistry: Using digoxigenin-dUTP or biotin-dUTP [14].
Guidelines for Sample Collection
Accuracy depends on proper collection techniques:
Bone Marrow Aspiration: A minimum volume of 2.5 ml is required.
Blood Samples: Collected in an EDTA (lavender-capped) tube. A minimum of 6.0 ml is required, with 3.0 ml to be placed in each of two tubes.
Tissue Samples: Tissues may be submitted in Hank’s fluid or as formalin-fixed, paraffin-embedded tissue.
Processing Protocol for Plasma/ctDNA Analysis
| (A) Blood Draw | (B) Centrifuge | (C) Storage |
| Blood draw with an anticoagulant such as EDTA | Centrifuge at 1200-1600 g for 10 minutes | Harvest supernatant; follow with a second high-speed centrifuge at 3000-16,000 g for 10 minutes; take supernatant into a fresh tube |
Transportation of Samples and Clinical Significance
To prevent the degradation of nucleic acids, samples must be handled with strict adherence to conditions. Specimens should be transported at ambient temperature and must reach the laboratory within 8 hours. If aspiration is performed, bone marrow smears should accompany the sample, along with a duly completed Surgical Pathology Request Form.
TdT is clinically significant as a marker for acute lymphoblastic leukemia (ALL) and serves as a diagnostic tool in distinguishing lymphoid from myeloid leukemia [6, 11, 12]. It also functions as a prognostic indicator and is useful in the management of lymphoid malignancies [6, 8]. Notably, elevated TdT levels have been associated with malnutrition and may act as a potential indicator of protein deficiency [14].
Clinical Limitations
TdT testing is not a standalone diagnostic for ALL and requires correlation with clinical morphology, immunophenotyping, and cytogenetics [6, 12]. Technical limitations include:
Homopolymer Formation: TdT can form homopolymer tails (e.g., AAAAAA) in the absence of a template, which may lead to non-specific binding [9].
Sensitivity: It is difficult to measure very low levels of TdT activity accurately [12].
References:
Bollum, F. J. (1974). Terminal deoxynucleotidyl transferase. The Enzymes, 10, 145–171.
Chang, L. M., & Bollum, F. J. (1986). Molecular biology of terminal transferase. CRC Critical Reviews in Biochemistry, 21(1), 27–52.
Landau, N. R., Schatz, D. G., Rosa, M., & Baltimore, D. (1987). Increased frequency of N-region insertion in a murine pre-B-cell line infected with a terminal deoxynucleotidyl transferase retroviral expression vector. Molecular and Cellular Biology, 7(9), 3237–3243.
Komori, T., Okada, A., Stewart, V., & Alt, F. W. (1993). Lack of N regions in antigen receptor variable region genes of T-cell-receptor-deficient mice. Science, 261(5125), 1171–1175.
Gilfillan, S., Benoist, C., & Mathis, D. (1993). Mice lacking terminal deoxynucleotidyl transferase: adult mice with few N regions and no diversity. Science, 261(5125), 1175–1178.
Pui, C. H., Behm, F. G., & Crist, W. M. (1993). Clinical and biologic relevance of immunologic marker studies in childhood acute lymphoblastic leukemia. Blood, 82(2), 343–362.
Deldar, A., Ghadially, F. N., & Kottamasu, S. R. (1985). Terminal deoxynucleotidyl transferase in acute lymphoblastic leukemia. Cancer, 56(8), 2011–2016.
Boué, F., Banchereau, J., & Dugas, B. (1986). TdT-positive cells in the bone marrow of patients with acute leukemia. Blood, 68(1), 162–167.
Ratliff, R. L., & Hoard, D. E. (1981). Terminal deoxynucleotidyl transferase: catalysis of the polymerization of deoxyribonucleotide triphosphates on primer substrates. Biochemistry, 20(15), 4443–4449.
Bollum, F. J. (1975). Terminal deoxynucleotidyl transferase: a hematopoietic cell marker. Blood, 45(3), 369–374.
McCaffrey, R., Smoler, D. F., & Baltimore, D. (1973). Terminal deoxynucleotidyl transferase in a case of childhood acute lymphoblastic leukemia. Proceedings of the National Academy of Sciences, 70(2), 521–525.
Coustan-Smith, E., Behm, F. G., & Campana, D. (1995). Terminal deoxynucleotidyl transferase analysis by flow cytometry in acute leukemia. American Journal of Clinical Pathology, 104(2), 167–175.
Srivastava, R. P., & Mcknight, G. S. (1990). Molecular biology of terminal deoxynucleotidyl transferase. Nucleic Acids Research, 18(17), 5035–5042.
Gilly, M., et al. (1997). Terminal deoxynucleotidyl transferase (TdT) expression in normal and malignant hematopoietic cells. Leukemia & Lymphoma, 27(1-2), 43–52.
Gu, H., et al. (1990). The role of TdT in V(D)J recombination. Cell, 62(5), 903–912.
FAQ’s:
What is TdT?
TdT is a template-independent DNA polymerase enzyme found in immature blood cells.Where is TdT found?
It is primarily expressed in immature, pre-B, and pre-T lymphoid cells.Why test for TdT?
It helps diagnose specific types of leukemia and lymphoma, like ALL.How is TdT detected?
It is detected using techniques like flow cytometry, immunohistochemistry, or the TUNEL assay.Is TdT a standalone test?
No, it must be correlated with morphology, immunophenotyping, and cytogenetic results.What samples are required?
The lab requires fresh bone marrow aspirate, peripheral blood, or tissue samples.How is the sample stored?
For ctDNA analysis, processed plasma is typically stored at -80 degrees Celsius.Can TdT identify leukemia?
Yes, it is a key diagnostic marker for acute lymphoblastic leukemia (ALL).Does TdT indicate malignancy?
Yes, it is a hallmark feature in cells of acute lymphoblastic leukemia and lymphoma.What causes elevated TdT?
Elevated levels may indicate blood malignancy or, in some cases, severe protein deficiency.
